Back
Delegates Premium Access

Prognostic value of HFA-PEFF and H2FPEF scores in patients with advanced cancer: a prospective observational study

Session: Who is at risk of cardiovascular toxicity?
Topic: Diagnosis and Management of Cardiovascular Disease in Patients with Cancer
Speaker: Doctor I. Baluta (Berlin, DE)
Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Iulia Baluta

Charité - University Medicine Berlin, Berlin (Germany)
0 follower

6 more presentations in this session

Cancer risks in heart failure patients: Insights from ischemic and non-ischemic cardiomyopathy

Speaker: Doctor S. Kim (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Unrecognized cardiovascular risks in young cervical cancer patients. Findings from the Rebuc study

Speaker: Doctor J. Hytting (Norrkoping, SE)

Access
Abstract
Slides
Like
Thumbnail

Three-year follow-up of anthracycline-induced cardiotoxicity risk in breast cancer patients using the HFA-ICOS score

Speaker: Doctor A. Amanova (Aktobe, KZ)

Access
Abstract
Slides
Like
Thumbnail

Framingham risk score associates with incident cancer and heart failure

Speaker: Doctor F. Van Den Berg (Rotterdam, NL)

Access
Abstract
Slides
Like
Thumbnail

Predictive capacity of the HFA-ICOS risk stratification scale for cardiovascular adverse events in patients treated with proteasome inhibitors

Speaker: Mr E. Pons-Fuster Lopez (Murcia, ES)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Who is at risk of cardiovascular toxicity?

Speakers: Doctor I. Baluta, Doctor S. Kim, Doctor J. Hytting, Doctor A. Amanova, Doctor F. Van Den Berg...
Access
Like
Thumbnail

About the event

Image

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources